Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HLA Antigens | 5 | 2021 | 35 | 2.350 |
Why?
|
| Kidney Transplantation | 23 | 2021 | 348 | 2.060 |
Why?
|
| Tissue Donors | 18 | 2020 | 167 | 1.950 |
Why?
|
| Alleles | 3 | 2021 | 251 | 1.610 |
Why?
|
| Graft Survival | 15 | 2021 | 228 | 1.100 |
Why?
|
| Exons | 2 | 2021 | 49 | 0.990 |
Why?
|
| Histocompatibility Testing | 3 | 2020 | 15 | 0.920 |
Why?
|
| Genotype | 5 | 2021 | 735 | 0.900 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 65 | 0.720 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 10 | 0.700 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 58 | 0.680 |
Why?
|
| Pancreas Transplantation | 6 | 2021 | 80 | 0.640 |
Why?
|
| Mutation | 1 | 2020 | 466 | 0.620 |
Why?
|
| Complement C4 | 1 | 2013 | 4 | 0.470 |
Why?
|
| Graft Rejection | 6 | 2018 | 149 | 0.470 |
Why?
|
| Gene Dosage | 1 | 2013 | 34 | 0.470 |
Why?
|
| Tissue and Organ Procurement | 6 | 2018 | 69 | 0.410 |
Why?
|
| Apolipoproteins | 4 | 2016 | 196 | 0.380 |
Why?
|
| Lipoproteins, HDL | 4 | 2016 | 247 | 0.370 |
Why?
|
| Histocompatibility | 2 | 2020 | 5 | 0.360 |
Why?
|
| Donor Selection | 3 | 2019 | 31 | 0.350 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 83 | 0.330 |
Why?
|
| Humans | 31 | 2023 | 29093 | 0.330 |
Why?
|
| Female | 25 | 2023 | 18164 | 0.290 |
Why?
|
| Retrospective Studies | 17 | 2021 | 3111 | 0.280 |
Why?
|
| Male | 24 | 2021 | 17807 | 0.280 |
Why?
|
| Adult | 23 | 2021 | 8420 | 0.260 |
Why?
|
| Kidney | 4 | 2021 | 485 | 0.230 |
Why?
|
| Hemophilia A | 1 | 2023 | 17 | 0.230 |
Why?
|
| Middle Aged | 21 | 2021 | 10829 | 0.220 |
Why?
|
| Survival Rate | 9 | 2018 | 795 | 0.220 |
Why?
|
| Kidney Diseases | 2 | 2015 | 239 | 0.210 |
Why?
|
| C-Peptide | 3 | 2021 | 25 | 0.210 |
Why?
|
| Cadaver | 8 | 2018 | 143 | 0.200 |
Why?
|
| African Americans | 4 | 2016 | 1373 | 0.200 |
Why?
|
| Delayed Graft Function | 3 | 2018 | 33 | 0.190 |
Why?
|
| Follow-Up Studies | 9 | 2019 | 2108 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 180 | 0.180 |
Why?
|
| Computational Biology | 1 | 2020 | 86 | 0.180 |
Why?
|
| Gene Frequency | 1 | 2020 | 225 | 0.180 |
Why?
|
| Codon | 1 | 2019 | 7 | 0.170 |
Why?
|
| Recombination, Genetic | 1 | 2019 | 20 | 0.170 |
Why?
|
| Laboratories | 1 | 2019 | 13 | 0.170 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 139 | 0.170 |
Why?
|
| Genetic Variation | 2 | 2021 | 251 | 0.160 |
Why?
|
| Organ Transplantation | 1 | 2019 | 65 | 0.160 |
Why?
|
| Risk Factors | 9 | 2018 | 3531 | 0.160 |
Why?
|
| Cold Ischemia | 1 | 2018 | 7 | 0.160 |
Why?
|
| Patient Selection | 3 | 2014 | 257 | 0.160 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2008 | 35 | 0.160 |
Why?
|
| Kidney Failure, Chronic | 2 | 2016 | 518 | 0.150 |
Why?
|
| Bone Transplantation | 2 | 2008 | 47 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2016 | 3099 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2016 | 111 | 0.130 |
Why?
|
| Caveolin 1 | 1 | 2015 | 13 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 231 | 0.130 |
Why?
|
| Immunosuppression | 3 | 2011 | 80 | 0.130 |
Why?
|
| Postoperative Complications | 2 | 2018 | 670 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 1079 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 4 | 2018 | 287 | 0.120 |
Why?
|
| Age Factors | 5 | 2019 | 1108 | 0.110 |
Why?
|
| Aged | 9 | 2021 | 9487 | 0.110 |
Why?
|
| Young Adult | 5 | 2019 | 2402 | 0.110 |
Why?
|
| Kidney Function Tests | 3 | 2018 | 102 | 0.100 |
Why?
|
| Prognosis | 4 | 2018 | 1362 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 366 | 0.100 |
Why?
|
| Postoperative Period | 3 | 2021 | 91 | 0.100 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 167 | 0.100 |
Why?
|
| Perfusion | 2 | 2008 | 64 | 0.100 |
Why?
|
| Nephrotic Syndrome | 1 | 2009 | 12 | 0.090 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 12 | 0.090 |
Why?
|
| Antilymphocyte Serum | 1 | 2009 | 17 | 0.090 |
Why?
|
| Adolescent | 6 | 2019 | 3254 | 0.090 |
Why?
|
| Molecular Motor Proteins | 1 | 2009 | 58 | 0.090 |
Why?
|
| Myosin Heavy Chains | 1 | 2009 | 86 | 0.090 |
Why?
|
| Portal System | 1 | 2008 | 6 | 0.080 |
Why?
|
| Extracorporeal Circulation | 1 | 2008 | 11 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 196 | 0.080 |
Why?
|
| Organ Preservation | 1 | 2007 | 13 | 0.080 |
Why?
|
| Creatinine | 3 | 2016 | 174 | 0.080 |
Why?
|
| Pancreas | 2 | 2021 | 79 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 709 | 0.070 |
Why?
|
| Time Factors | 4 | 2016 | 2001 | 0.070 |
Why?
|
| Transplantation Immunology | 1 | 2005 | 27 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2005 | 41 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2019 | 1167 | 0.060 |
Why?
|
| North Carolina | 3 | 2015 | 1423 | 0.060 |
Why?
|
| Hypertension | 1 | 2011 | 906 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2021 | 859 | 0.060 |
Why?
|
| Phenotype | 2 | 2016 | 629 | 0.060 |
Why?
|
| Blood Coagulation | 1 | 2023 | 12 | 0.060 |
Why?
|
| Factor VIII | 1 | 2023 | 19 | 0.060 |
Why?
|
| United States | 3 | 2017 | 3630 | 0.060 |
Why?
|
| Fetus | 1 | 2023 | 78 | 0.060 |
Why?
|
| Sheep | 1 | 2023 | 221 | 0.060 |
Why?
|
| Placenta | 1 | 2023 | 63 | 0.060 |
Why?
|
| Haplotypes | 2 | 2015 | 220 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2021 | 56 | 0.050 |
Why?
|
| Nephrectomy | 2 | 2016 | 114 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 293 | 0.050 |
Why?
|
| Infant | 2 | 2019 | 969 | 0.050 |
Why?
|
| Pregnancy | 1 | 2023 | 815 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2009 | 2019 | 0.040 |
Why?
|
| Child | 2 | 2019 | 2219 | 0.040 |
Why?
|
| Waiting Lists | 2 | 2008 | 30 | 0.040 |
Why?
|
| Death | 2 | 2008 | 41 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 440 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2008 | 113 | 0.040 |
Why?
|
| Animals | 2 | 2023 | 7297 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2011 | 1687 | 0.030 |
Why?
|
| Alabama | 1 | 2015 | 27 | 0.030 |
Why?
|
| Reoperation | 1 | 2016 | 203 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 31 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 148 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 447 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 278 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 637 | 0.030 |
Why?
|
| Disease Progression | 1 | 2014 | 572 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2015 | 1131 | 0.020 |
Why?
|
| Steroids | 1 | 2009 | 36 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 3717 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 185 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 114 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 464 | 0.020 |
Why?
|
| Immunization | 1 | 2008 | 28 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2008 | 67 | 0.020 |
Why?
|
| Drainage | 1 | 2008 | 49 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2007 | 37 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 198 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2007 | 42 | 0.020 |
Why?
|
| Orthopedic Procedures | 1 | 2008 | 92 | 0.020 |
Why?
|
| Wound Healing | 1 | 2008 | 182 | 0.020 |
Why?
|
| Body Size | 1 | 2006 | 31 | 0.020 |
Why?
|
| Cause of Death | 1 | 2007 | 220 | 0.020 |
Why?
|
| Nephrons | 1 | 2006 | 10 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2006 | 134 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1379 | 0.010 |
Why?
|